[Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].

نویسندگان

  • Mitsuo Saito
  • Mutsuko Hirata-Koizumi
  • Shinji Miyake
  • Ryuichi Hasegawa
چکیده

The number of new molecular entities (NMEs) approved in 2005 was 17 in Japan, 20 in US and 18 in EU, respectively. Among 53 NMEs approved in Japan and at least one other region during 2002 to 2005, 53 NMEs had been approved in US and 25 in EU by 2005, but there were no common approvals only between Japan and EU. On the other hand, 26 NMEs were solely approved in US and EU during this period. Among 79 NMEs approved in either two or three regions, the number of preceding NMEs was 3 in Japan, 62 in U.S. and 14 in EU.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?

In their cautious review, Shah and Shah [1] emphasized differences in regulations of personalized medicine (PM) among the three major authorities, the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Specific points regarding the differences, however, were not raised for the drugs they selected for dis...

متن کامل

Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis

BACKGROUND Epilepsy is a serious chronic health condition with a high morbidity impairing the life of patients and afflicted families. Many epileptic conditions, especially those affecting children, are rare disorders generating an urgent medical need for more efficacious therapy options. Therefore, we assessed the output of the US and European orphan drug legislations. METHODS Quantitative a...

متن کامل

Analysis of the Stringency of Drinking Water Quality Standards of Bangladesh in Comparison to the USA, EU, Japanese, and Indian Standards

Water is one of the most crucial substances for life. In order to maintain their public health, each and every country has defined standards of drinking water quality, beyond which the water is considered harmful for human health. The current study compares physical, chemical, and biological standards of drinking water quality for the USA, EU, Japan, India, and Bangladesh, considering 4 physica...

متن کامل

Analysis of the Stringency of Drinking Water Quality Standards of Bangladesh in Comparison to the USA, EU, Japanese, and Indian Standards

Water is one of the most crucial substances for life. In order to maintain their public health, each and every country has defined standards of drinking water quality, beyond which the water is considered harmful for human health. The current study compares physical, chemical, and biological standards of drinking water quality for the USA, EU, Japan, India, and Bangladesh, considering 4 physica...

متن کامل

Incentives for orphan drug research and development in the United States

BACKGROUND The Orphan Drug Act (1983) established several incentives to encourage the development of orphan drugs (ODs) to treat rare diseases and conditions. This study analyzed the characteristics of OD designations, approvals, sponsors, and evaluated the effective patent and market exclusivity life of orphan new molecular entities (NMEs) approved in the US between 1983 and 2007. METHODS Pr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo hokoku = Bulletin of National Institute of Health Sciences

دوره 124  شماره 

صفحات  -

تاریخ انتشار 2006